Literature DB >> 25560713

Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis.

Raveendhara R Bannuru, Christopher H Schmid, David M Kent, Elizaveta E Vaysbrot, John B Wong, Timothy E McAlindon.   

Abstract

BACKGROUND: The relative efficacy of available treatments of knee osteoarthritis (OA) must be determined for rational treatment algorithms to be formulated.
PURPOSE: To examine the efficacy of treatments of primary knee OA using a network meta-analysis design, which estimates relative effects of all treatments against each other. DATA SOURCES: MEDLINE, EMBASE, Web of Science, Google Scholar, Cochrane Central Register of Controlled Trials from inception through 15 August 2014, and unpublished data. STUDY SELECTION: Randomized trials of adults with knee OA comparing 2 or more of the following: acetaminophen, diclofenac, ibuprofen, naproxen, celecoxib, intra-articular (IA) corticosteroids, IA hyaluronic acid, oral placebo, and IA placebo. DATA EXTRACTION: Two reviewers independently abstracted study data and assessed study quality. Standardized mean differences were calculated for pain, function, and stiffness at 3-month follow-up. DATA SYNTHESIS: Network meta-analysis was performed using a Bayesian random-effects model; 137 studies comprising 33,243 participants were identified. For pain, all interventions significantly outperformed oral placebo, with effect sizes from 0.63 (95% credible interval [CrI], 0.39 to 0.88) for the most efficacious treatment (hyaluronic acid) to 0.18 (CrI, 0.04 to 0.33) for the least efficacious treatment (acetaminophen). For function, all interventions except IA corticosteroids were significantly superior to oral placebo. For stiffness, most of the treatments did not significantly differ from one another. LIMITATION: Lack of long-term data, inadequate reporting of safety data, possible publication bias, and few head-to-head comparisons.
CONCLUSION: This method allowed comparison of common treatments of knee OA according to their relative efficacy. Intra-articular treatments were superior to nonsteroidal anti-inflammatory drugs, possibly because of the integrated IA placebo effect. Small but robust differences were observed between active treatments. All treatments except acetaminophen showed clinically significant improvement from baseline pain. This information, along with the safety profiles and relative costs of included treatments, will be helpful for individualized patient care decisions. PRIMARY FUNDING SOURCE: Agency for Healthcare Research and Quality.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25560713     DOI: 10.7326/M14-1231

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  187 in total

Review 1.  The rise, fall, and possible resurrection of renal denervation.

Authors:  Rajiv Gulati; Claire E Raphael; Manuela Negoita; Stuart J Pocock; Bernard J Gersh
Journal:  Nat Rev Cardiol       Date:  2016-02-04       Impact factor: 32.419

2.  American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain.

Authors:  Amanda M Brandow; C Patrick Carroll; Susan Creary; Ronisha Edwards-Elliott; Jeffrey Glassberg; Robert W Hurley; Abdullah Kutlar; Mohamed Seisa; Jennifer Stinson; John J Strouse; Fouza Yusuf; William Zempsky; Eddy Lang
Journal:  Blood Adv       Date:  2020-06-23

3.  Non-steroidal anti-inflammatory drugs and risk of cerebrovascular events in patients with osteoarthritis: a nested case-control study.

Authors:  Francesco Lapi; Carlo Piccinni; Monica Simonetti; Miriam Levi; Pierangelo Lora Aprile; Iacopo Cricelli; Claudio Cricelli; Andrea Fanelli
Journal:  Intern Emerg Med       Date:  2015-08-14       Impact factor: 3.397

4.  Effect of Mobile Device-Assisted N-of-1 Trial Participation on Analgesic Prescribing for Chronic Pain: Randomized Controlled Trial.

Authors:  David D Odineal; Maria T Marois; Deborah Ward; Christopher H Schmid; Rima Cabrera; Ida Sim; Youdan Wang; Barth Wilsey; Naihua Duan; Stephen G Henry; Richard L Kravitz
Journal:  J Gen Intern Med       Date:  2019-08-28       Impact factor: 5.128

5.  Value-based Healthcare: The Challenge of Identifying and Addressing Low-value Interventions.

Authors:  Michael G Zywiel; Tiffany C Liu; Kevin J Bozic
Journal:  Clin Orthop Relat Res       Date:  2017-03-02       Impact factor: 4.176

6.  Practice guidelines for pharmacists: The management of osteoarthritis.

Authors:  Jason Kielly; Erin M Davis; Carlo Marra
Journal:  Can Pharm J (Ott)       Date:  2017-05-01

7.  Cochrane in CORR®: Intra-articular Corticosteroid For Knee Osteoarthritis.

Authors:  Moin Khan; Mohit Bhandari
Journal:  Clin Orthop Relat Res       Date:  2018-07       Impact factor: 4.176

8.  EUROVISCO Guidelines for the Design and Conduct of Clinical Trials Assessing the Disease-Modifying Effect of Knee Viscosupplementation.

Authors:  Yves Henrotin; Xavier Chevalier; Raghu Raman; Pascal Richette; Jordi Montfort; Jörg Jerosch; Dominique Baron; Hervé Bard; Yannick Carrillon; Alberto Migliore; Thierry Conrozier
Journal:  Cartilage       Date:  2018-07-04       Impact factor: 4.634

Review 9.  Natural Products for Promoting Joint Health and Managing Osteoarthritis.

Authors:  Yves Henrotin; Ali Mobasheri
Journal:  Curr Rheumatol Rep       Date:  2018-09-19       Impact factor: 4.592

10.  Decision Algorithms for the Retreatment with Viscosupplementation in Patients Suffering from Knee Osteoarthritis: Recommendations from the EUROpean VIScosupplementation COnsensus Group (EUROVISCO).

Authors:  Raghu Raman; Yves Henrotin; Xavier Chevalier; Alberto Migliore; Jörg Jerosch; Jordi Montfort; Hervé Bard; Dominique Baron; Pascal Richette; Thierry Conrozier
Journal:  Cartilage       Date:  2017-02-01       Impact factor: 4.634

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.